Captrust Financial Advisors Buys Shares of 15,820 Vir Biotechnology, Inc. (NASDAQ:VIR)

Captrust Financial Advisors bought a new stake in Vir Biotechnology, Inc. (NASDAQ:VIR) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 15,820 shares of the company’s stock, valued at approximately $118,000.

Several other large investors also recently added to or reduced their stakes in VIR. Millennium Management LLC grew its holdings in Vir Biotechnology by 94.6% in the 2nd quarter. Millennium Management LLC now owns 1,248,131 shares of the company’s stock valued at $11,108,000 after buying an additional 606,804 shares in the last quarter. Federated Hermes Inc. grew its holdings in shares of Vir Biotechnology by 19,327.1% during the 2nd quarter. Federated Hermes Inc. now owns 300,148 shares of the company’s stock worth $2,671,000 after purchasing an additional 298,603 shares during the period. Affinity Asset Advisors LLC purchased a new position in shares of Vir Biotechnology during the 2nd quarter worth $1,780,000. Cubist Systematic Strategies LLC grew its holdings in shares of Vir Biotechnology by 6,402.0% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 188,624 shares of the company’s stock worth $1,679,000 after purchasing an additional 185,723 shares during the period. Finally, Algert Global LLC purchased a new position in shares of Vir Biotechnology during the 2nd quarter worth $1,485,000. 65.32% of the stock is currently owned by hedge funds and other institutional investors.

Vir Biotechnology Trading Up 1.5 %

VIR opened at $7.56 on Tuesday. The stock’s 50-day moving average price is $8.03 and its 200 day moving average price is $8.61. Vir Biotechnology, Inc. has a 12-month low of $6.56 and a 12-month high of $13.09. The firm has a market cap of $1.04 billion, a price-to-earnings ratio of -1.93 and a beta of 0.49.

Vir Biotechnology (NASDAQ:VIR) last posted its earnings results on Thursday, October 31st. The company reported ($1.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.05) by ($0.51). Vir Biotechnology had a negative return on equity of 36.71% and a negative net margin of 678.40%. The firm had revenue of $2.38 million for the quarter, compared to analyst estimates of $5.54 million. During the same period in the previous year, the company posted ($1.22) EPS. Vir Biotechnology’s revenue was down 9.8% on a year-over-year basis. On average, research analysts forecast that Vir Biotechnology, Inc. will post -3.36 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on VIR. Needham & Company LLC reiterated a “buy” rating and set a $19.00 price target on shares of Vir Biotechnology in a report on Wednesday, November 20th. HC Wainwright reiterated a “buy” rating and set a $110.00 price target on shares of Vir Biotechnology in a report on Wednesday, November 20th. Finally, Barclays lowered their price target on Vir Biotechnology from $28.00 to $26.00 and set an “overweight” rating for the company in a report on Monday, November 4th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $36.40.

Vir Biotechnology Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).